Signos cutáneos del maltrato infantil

Autor: Pau-Charles, I., Darwich-Soliva, E., Grimalt, R.

Publikováno v: In Actas dermosifiliograficas March 2012 103(2):94-99

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2

Autor: Fernandez, A. P., Dauden, E., Gerdes, S., Lebwohl, M. G., Menter, M. A., Leonardi, C. L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J. P., Bianchi, L., Egeberg, A., Pau-Charles, I., Mendelsohn, A. M., Rozzo, S. J., Mehta, N. N.

Publikováno v: Fernandez, A P, Dauden, E, Gerdes, S, Lebwohl, M G, Menter, M A, Leonardi, C L, Gooderham, M, Gebauer, K, Tada, Y, Lacour, J P, Bianchi, L, Egeberg, A, Pau-Charles, I, Mendelsohn, A M, Rozzo, S J & Mehta, N N 2022, ' Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome : post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2 ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 10, pp. 1774-1783 . https://doi.org/10.1111/jdv.18167

Background: Limited data are available on long-term efficacy and safety of biologics in patients with psoriasis and metabolic syndrome (MetS), a common comorbidity. Objectives: This analysis updates tildrakizumab efficacy and safety for up to 5 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1bdc916438aced2f09ca0b3e06780342
https://pubmed.ncbi.nlm.nih.gov/35460287

108 Protein profile following therapy with DMF in patients with plaque psoriasis

Autor: Rane, S.S., Foulkes, A., Morris, A.P., Pau-Charles, I., Eyre, S., Warren, R.B.

Publikováno v: Journal of Investigative Dermatology; December 2024, Vol. 144 Issue: 12, Number 12 Supplement 1 pS246-S246, 1p

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis:pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

Autor: Reich, K., Warren, R. B., Iversen, L., Puig, L., Pau-Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M. G., Cantrell, W., Blauvelt, A., Thaçi, D.

Publikováno v: Reich, K, Warren, R B, Iversen, L, Puig, L, Pau-Charles, I, Igarashi, A, Ohtsuki, M, Falqués, M, Harmut, M, Rozzo, S, Lebwohl, M G, Cantrell, W, Blauvelt, A & Thaçi, D 2020, ' Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks ', British Journal of Dermatology, vol. 182, no. 3, pp. 605-617 . https://doi.org/10.1111/bjd.18232
Reich, K, Warren, R B, Iversen, L, Puig, L, Pau-Charles, I, Igarashi, A, Ohtsuki, M, Falqués, M, Harmut, M, Rozzo, S, Lebwohl, M G, Cantrell, W, Blauvelt, A & Thaçi, D 2019, ' Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks ', British Journal of Dermatology . https://doi.org/10.1111/bjd.18232

BACKGROUND: Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis.OBJECTIVES: To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-sever

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2d9bd08b08c77bad03fe73c54b6b1e41
https://pure.au.dk/ws/files/220038888/bjd.18232.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.